Debating the way to lung cancer. The international and Italian viewpoint Milano, 9 marzo 2017
Hilton Milan - Via Galvani, 12
RATIONAL
The paradigm of lung cancer therapy has changed greatly over the last few years.
The program aims at sharing with the medical community clinical guidance and thoughts for the management of patients with lung cancer.
Recent advances in tumour genome molecular analysis revealed that dysregulated signals of a number of proto-oncogenes, and of epidermal growth factor receptor (EGFR) in particular, play a key role in profiling lung cancer patients and therefore in performing the most appropriate therapeutic choice.
With these new diagnostic possibilities, new classes of drugs are revolutionizing therapy in lung cancer: immunotherapy, anti-angiogenic therapy and target therapy.
The optimal therapeutic sequence is the one tailored on the medical history of each patient;
however, the results coming from clinical trials, clinical practice and guidelines are inescapable resources to be recognized for an evidence-based medicine approach.
Hence the importance of sharing experiences in Italy and at international level.
This event program, gathering together knowledge and expertise of a panel of experts, addresses key issues and current understanding in the diagnosis, staging and treatment of lung cancer by exploring the best patient-centred clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic.
Debating the way to lung cancer. The international and Italian viewpoint Milano, 9 marzo 2017
Hilton Milan - Via Galvani, 12 h. 9.00 – 19.00
PROGRAMMA SCIENTIFICO
9.00 – 9.30 Accoglienza e Registrazione
9.30 – 10.00 Apertura Lavori, introduzione e obiettivi dell’incontro Diego Cortinovis Vanesa Gregorc PRIMA SESSIONE – Moderatore: Alessandra Bearz
10.00 – 10.30 L’approccio terapeutico e l’esperienza clinica dell’est Europa nei pazienti con NSCLC EGFR mutati
Rafal Dziadziuszko
10.30 – 11.00 Pros & Contra. Marcello Tiseo
11.00 – 11.30 Discussione plenaria Modera A. Bearz
SECONDA SESSIONE – Moderatore: Mariarita Migliorino 11.30 – 12.00 L’approccio terapeutico e l’esperienza clinica del nord
Europa nei pazienti con NSCLC, adenocarcinoma, wild type
Christian Rolfo
12.00 – 12.30 Pros & Contra. Diego Cortinovis
12.30 – 13.00 Discussione plenaria Modera M. Migliorino
13.00 – 14.00 LUNCH
TERZA SESSIONE – Moderatore: TBD
14.00 – 14.30 Percorso terapeutico nel paziente EGFR mutato Domenico Galetta 14.30 – 15.00 Percorso terapeutico nel paziente W.T. Vanesa Gregorc
15.00 – 15.30 Aspetti biomolecolari dei percorsi Umberto Malapelle
15.30 – 16.00 Discussione plenaria
16.00 – 16.30 Espressione di accordo All
QUARTA SESSIONE – Moderatore: Alessandro Morabito 16.30 – 18.00 Round table: approccio europeo alla ricerca clinica
18.00 – 19.00 Conclusioni / Wrap-up and closing remarks A. Bearz, D. Cortinovis, D. Galetta, V. Gregorc, M. Migliorino, A.
Morabito, M. Tiseo, U.Malapelle,
C. Rolfo, M. Schuler, R. Dziadziuszko
